Your session is about to expire
← Back to Search
Rituximab for EBV Infection
Study Summary
This trial is testing whether giving the donor lungs a dose of rituximab can decrease the amount of B-cells and EBV in the graft, which may prevent the EBV from being transmitted to the patient.
- Epstein-Barr Virus (EBV) Infection
- Lymphoproliferative Disorder
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 & 3 trial • 86 Patients • NCT03002038Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are some of the primary indications for Rituximab?
"Rituximab is an effective treatment for diffuse large b-cell lymphoma (dlbcl), b-cell lymphomas, and polyangium."
Are there any current openings in this trial for eligible participants?
"That is accurate, the clinical trial detailed on clinicaltrials.gov is currently looking for subjects. The date the study was first posted was July 7th, 2020 with the most recent update being from July 29th, 2022. There is a need for 10 individuals at 1 location."
How many people are being included in this research project?
"The clinicaltrial.gov website has information revealing that this study is looking for 10 participants at 1 sites. The trial was first posted on 7/7/2020 and was most recently edited on 7/29/2022."
Share this study with friends
Copy Link
Messenger